# OakLabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oaklabs

- Industry: Biotechnology
- Headquarters: Hennigsdorf, Germany
- Website: www.oak-labs.com
- Latest round: Seed (Feb 9, 2012)
- Investors on record: 1

## About

OakLabs GmbH develops advanced laboratory analyses and proprietary AI algorithms to enhance preventative healthcare. Their innovative solutions focus on health monitoring, leveraging cutting-edge technology for early detection of health conditions.Founded by Martina Schad, OakLabs GmbH specializes in advanced health technologies, operating from its headquarters in Hennigsdorf, Germany. The company raised Seed financing from High-Tech Gründerfonds on February 9, 2012, to support its growth initiatives. CEO Erdmann Flindt oversees the company's strategic direction and operations, driving their mission to provide scientific health solutions.OakLabs Scientific specializes in advanced laboratory analyses and proprietary artificial intelligence algorithms aimed at preventative health care. Their core product offerings include a science-based health monitor, which analyzes amino acid profiles in blood samples, allowing early detection of critical health conditions. Additionally, they leverage their AI engine to create highly accurate biomarkers that integrate multiple relevant molecules, providing insights into biological states such as disease and drug efficacy. In 2023, OakLabs expanded its services to individual consumers, making their state-of-the-art analyses accessible beyond industry and research clients, which include various sectors in healthcare and biotechnology. The geographic markets served encompass international clients across Europe, North America, and other global regions, where they seek to enhance health outcomes through data-driven solutions.OakLabs Scientific generates revenue through direct-to-consumer health monitoring services as well as partnerships with industry clients for custom laboratory analyses. Their business model includes selling health test kits to individuals, providing results alongside personalized recommendations, which strengthens customer engagement and loyalty. The structure of transactions is primarily B2C for individual customers, while B2B relationships with research and industry partners facilitate tailored solutions and analyses. Specific pricing plans and service costs are determined based on the nature of the analyses requested and the complexity of the data provided. Key products include the health monitor and biomarker analyses, which are integral to their revenue strategy, supporting a comprehensive approach to preventative health care.OakLabs GmbH plans to introduce new health monitoring products aimed at enhancing user experience, with a potential launch timeframe set for late 2024. The company aims to expand into key markets in Asia and South America by 2025, broadening its consumer base. The funds raised in the Seed financing round in February 2012 will continue to support these initiatives, facilitating research and development efforts to innovate and maintain competitiveness in the evolving health technology landscape.

## Funding rounds

- Seed, Feb 9, 2012 — High-Tech Gruenderfonds

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed